Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
October 24 2024 - 6:30AM
UK Regulatory
Biogen to Present New Data at the Clinical Trials on Alzheimer's
Disease (CTAD) 2024 Annual Conference
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) --
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations
and programming at the Clinical Trials on Alzheimer’s Disease
(CTAD) annual conference, taking place October 29 - November 1, in
Madrid, Spain. The presentations will include updates on new
scientific findings from Biogen’s Alzheimer’s portfolio,
highlighting data on different aspects of treatment and data
examining preclinical Alzheimer’s disease and race.
“These data showcase the breadth of our Alzheimer’s disease
research and our ongoing commitment to scientific innovation,” said
Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “We
remain dedicated to advancing the field of research and treatment
for this disease in order to better serve the millions of patients,
families and providers in the Alzheimer’s community.”
Key Presentations and Symposia:
- Transitioning from Clinical Trial to Clinical Practice for
Long-Term Lecanemab Treatment in Early Alzheimer's Disease:
Perspectives from an Alzheimer's Disease Treatment Center,
Tuesday, October 29
- The AHEAD 3-45 Study: Design and Results of a Novel Screening
Process for a Preclinical AD Trial, Tuesday, October 29, 6:10
PM
- Does the Current Evidence Base Support Continued Dosing with
Lecanemab for Early Alzheimer's Disease? Wednesday, October 30,
9:40 AM
- Lecanemab for the Treatment of Mild Cognitive Impairment and
Mild Dementia Due to Alzheimer's Disease in Adults That Are
Apoliprotein E ɛ4 Heterozygotes or Non-Carriers, Wednesday,
October 30, 11:20 AM
- One-Year Experience on the Use of Lecanemab in Clinical
Practice, Wednesday, October 30, 3:30 PM
- AI-Derived Prognostic Covariates Enhance the Precision of
Lecanemab Efficacy Assessments and Optimize Alzheimer's Disease
Clinical Trials, Thursday, October 31, 3:25 PM
- Estimating by race and APOE Ɛ4 carrier status counts of US
adults with subjective cognitive decline with preclinical
Alzheimer’s disease, Friday, November 1
Virtual Experience on Tau Pathology
At the meeting, Biogen will also host a virtual booth for attendees
exploring the role of tau in Alzheimer’s disease, including an
interactive medical education e-learning module on knowtau.com
which has more information on tau pathophysiology.
For more information, please see the CTAD 2024 program and visit
the Biogen CTAD virtual booth.
About LEQEMBI® (lecanemab)
LEQEMBI (lecanemab) is the result of a strategic research alliance
between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin
gamma 1 (IgG1) monoclonal antibody directed against aggregated
soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
LEQEMBI is an amyloid beta-directed antibody for the treatment for
Alzheimer’s disease (AD) in the U.S. The U.S. Food and Drug
Administration (FDA) granted LEQEMBI traditional approval on July
6, 2023.
LEQEMBI is indicated for the treatment of Alzheimer’s disease.
Treatment with LEQEMBI should be initiated in patients with mild
cognitive impairment or mild dementia stage of disease, the
population in which treatment was initiated in clinical trials.
Eisai and Biogen have been collaborating on the joint
development and commercialization of AD treatments since 2014.
Eisai serves as the lead of LEQEMBI development and regulatory
submissions globally with both companies co-commercializing and
co-promoting the product and Eisai having final decision-making
authority.
Please see full U.S. Prescribing Information for
LEQEMBI, including Boxed WARNING and Medication Guide.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that
pioneers innovative science to deliver new medicines to transform
patient’s lives and to create value for shareholders and our
communities. We apply deep understanding of human biology and
leverage different modalities to advance first-in-class treatments
or therapies that deliver superior outcomes. Our approach is to
take bold risks, balanced with return on investment to deliver
long-term growth.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, about the
potential clinical effects of lecanemab; the potential benefits,
safety and efficacy of lecanemab; potential regulatory discussions,
submissions and approvals and the timing thereof; the treatment of
Alzheimer's disease; the anticipated benefits and potential of
Biogen's collaboration arrangements with Eisai; the potential of
Biogen's commercial business and pipeline programs; including
lecanemab; and risks and uncertainties associated with drug
development and commercialization. These statements may be
identified by words such as "aim," "anticipate," "believe,"
"could," "estimate," "expect," "forecast," "intend," "may," "plan,"
"possible," "potential," "will," "would" and other words and terms
of similar meaning. Drug development and commercialization involve
a high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Results in early-stage clinical studies may not be indicative of
full results or results from later stage or larger scale clinical
studies and do not ensure regulatory approval. You should not place
undue reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation unexpected concerns
that may arise from additional data, analysis or results obtained
during clinical studies; the occurrence of adverse safety events;
risks of unexpected costs or delays; the risk of other unexpected
hurdles; regulatory submissions may take longer or be more
difficult to complete than expected; regulatory authorities may
require additional information or further studies, or may fail or
refuse to approve or may delay approval of Biogen's drug
candidates; including lecanemab; actual timing and content of
submissions to and decisions made by the regulatory authorities
regarding lecanemab; uncertainty of success in the development and
potential commercialization of the medicine; failure to protect and
enforce Biogen's data, intellectual property and other proprietary
rights and uncertainties relating to intellectual property claims
and challenges; product liability claims; and third party
collaboration risks, results of operations and financial condition.
The foregoing sets forth many, but not all, of the factors that
could cause actual results to differ from Biogen's expectations in
any forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in
Biogen's most recent annual or quarterly report and in other
reports Biogen has filed with the U.S. Securities and Exchange
Commission. These statements speak only as of the date of this news
release. Biogen does not undertake any obligation to publicly
update any forward-looking statements.
MEDIA CONTACT(S):
Biogen
Jack Cox
+ 1 781 464 3260
public.affairs@biogen.com
|
INVESTOR CONTACT(S):
Biogen
Stephen Amato
+1 781 464 2442
IR@biogen.com
|
Biogen (BIT:1BIIB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biogen (BIT:1BIIB)
Historical Stock Chart
From Dec 2023 to Dec 2024